{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:46:41Z","timestamp":1790192801466,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1053\/j.ajkd.2014.01.434","type":"journal-article","created":{"date-parts":[[2014,3,21]],"date-time":"2014-03-21T20:22:27Z","timestamp":1395433347000},"page":"633-637","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":177,"title":["Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome: A Report of 10 Cases"],"prefix":"10.1053","volume":"64","author":[{"given":"Gianluigi","family":"Ardissino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Possenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Paglialonga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Salardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Belingheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2014.01.434_bib1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.med.59.060106.185110","article-title":"Complement regulatory genes and hemolytic uremic syndromes","volume":"59","author":"Kavanagh","year":"2008","journal-title":"Annu Rev Med"},{"issue":"8","key":"10.1053\/j.ajkd.2014.01.434_bib2","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2014.01.434_bib3","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.transproceed.2010.09.125","article-title":"Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report","volume":"42","author":"Ch\u00e2telet","year":"2010","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1053\/j.ajkd.2014.01.434_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00431-009-1039-4","article-title":"Clinical practice. Today's understanding of the haemolytic uraemic syndrome","volume":"169","author":"Scheiring","year":"2010","journal-title":"Eur J Pediatr"},{"issue":"6","key":"10.1053\/j.ajkd.2014.01.434_bib5","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.ajkd.2004.02.010","article-title":"Non-enteropathic hemolytic uremic syndrome: causes and short-term course","volume":"43","author":"Constantinescu","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2014.01.434_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1365-2141.2009.07916.x","article-title":"Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom","volume":"148","author":"Taylor","year":"2010","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.ajkd.2014.01.434_bib7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00467-013-2423-x","article-title":"Atypical HUS: time to take stock of current guidelines and outcome measures?","volume":"28","author":"Rees","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ajkd.2014.01.434_bib8","first-page":"45","article-title":"Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report","volume":"3","author":"Ohanian","year":"2011","journal-title":"Clin Pharmacol"},{"issue":"2","key":"10.1053\/j.ajkd.2014.01.434_bib9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","article-title":"Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome","volume":"115","author":"Moore","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.ajkd.2014.01.434_bib10","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2014.01.434_bib11","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MOH.0b013e32833cae86","article-title":"Atypical hemolytic uremic syndrome","volume":"17","author":"Kavanagh","year":"2010","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1053\/j.ajkd.2014.01.434_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1160\/TH08-05-0322","article-title":"Autoantibodies in haemolytic uraemic syndrome (HUS)","volume":"101","author":"Skerka","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.ajkd.2014.01.434_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ckj\/sfr177","article-title":"Treatment of atypical uremic syndrome in the era of eculizumab","volume":"5","author":"Fremeaux-Bacchi","year":"2012","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.ajkd.2014.01.434_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00467-012-2296-4","article-title":"Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab","volume":"28","author":"Besbas","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2014.01.434_bib15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1055\/s-0030-1262889","article-title":"New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab","volume":"36","author":"K\u00f6se","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1053\/j.ajkd.2014.01.434_bib16","unstructured":"FDA. News release September 23, 2011. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm272990.htm. Accessed March 13, 2014."},{"issue":"1","key":"10.1053\/j.ajkd.2014.01.434_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2010.155","article-title":"New insights into postrenal transplant hemolytic uremic syndrome","volume":"7","author":"Zuber","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2014.01.434_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMc0809959","article-title":"Eculizumab for congenital atypical hemolytic-uremic syndrome","volume":"360","author":"Gruppo","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2014.01.434_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1053\/j.ajkd.2014.01.434_bib20","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00467-012-2276-8","article-title":"Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome","volume":"27","author":"Vilalta","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ajkd.2014.01.434_bib21","unstructured":"European Medicines Agency. Soliris (online). http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000791\/human_med_001055.jsp&mid=WC0b01ac058001d24 (2012). Accessed March 13, 2014."},{"issue":"6","key":"10.1053\/j.ajkd.2014.01.434_bib22","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00277-012-1622-z","article-title":"Relapse of aHUS after discontinuation of therapy with eculizumab in a patient with aHUS and factor H mutation","volume":"92","author":"Carr","year":"2013","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1053\/j.ajkd.2014.01.434_bib23","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2014.01.434_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2010.155","article-title":"New insights into post-renal transplant hemolytic uremic syndrome","volume":"7","author":"Zuber","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2014.01.434_bib25","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00467-012-2283-9","article-title":"Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation","volume":"27","author":"Cayci","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2014.01.434_bib26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00467-013-2416-9","article-title":"Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab","volume":"28","author":"Gulleroglu","year":"2013","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2014.01.434_bib27","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2014.01.434_bib28","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/CMR.00048-09","article-title":"Infections of people with complement deficiencies and patients who have undergone splenectomy","volume":"23","author":"Ram","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1053\/j.ajkd.2014.01.434_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2014.01.434_bib30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ajkd.2014.01.434_bib31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2014.01.434_bib32","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614005289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638614005289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:23:28Z","timestamp":1759458208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638614005289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0272638614005289"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.434","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718321887.793501522","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718321887.793498054","asserted-by":"object"}]},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome: A Report of 10 Cases","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2014.01.434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}